Clinical study for new targeted antioxidants in the treatment of m.3243A>G carriers

Molecular mechanism and treatment strategy of mitochondrial DNA 3243 (A>G) mutation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023786

Enrollment

Unknown

Registered

2019-06-11

Start date

2019-03-18

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

m.3243A>G

Interventions

Case series:MitoQ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Genetic screening confirmed as mt.3243A>G mutation patient; 2. Aged between 18 and 75 years old; 3. If it is a woman of childbearing age, the urine pregnancy test is negative; 4. The patient signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Female patients are pregnant, breastfeeding or planning a pregnancy during the trial; 2. Have obvious liver and kidney disease (ALT or AST is 2-3 times higher than the upper limit of normal, or T-Bil is 1.5 times higher than the upper limit of normal, or Cr>115µmol/L); 3. Suffering from unstable or severe angina pectoris, cardiac insufficiency (NYHA classification III/IV); 4. Suffering from chronic wasting diseases such as malignant tumors and tuberculosis, blood diseases, psychosis, autoimmune diseases, obvious digestive dysfunction, acute cerebrovascular disease in the past 6 months

Design outcomes

Primary

Measure	Time frame
blood glucose level;SNHL;blood pressure;blood lipid;Mitochondrial function;	—

Secondary

Measure	Time frame
cardiac function;MRS;FGMS;Bone density;	—

Countries

China

Contacts

Public ContactCongrong Wang

Shanghai 6th People's Hospital

crwang@sjtu.edu.cn+86 18930172121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026